The impact of generic-only drug benefits on patients' use of inhaled corticosteroids in a Medicare population with asthma

BMC Health Services Research

Volumn 8, Issue , 2008, Pages

  Fung, Vicki ^a   Tager, Ira B ^b   Brand, Richard ^c   Newhouse, Joseph P ^d,e,f   Hsu, John ^a  

^a DIVISION OF RESEARCH   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^f HARVARD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BECLOMETASONE DIPROPIONATE; CORTICOSTEROID; FLUTICASONE PROPIONATE; GENERIC DRUG; STEROID; ANTIASTHMATIC AGENT;

AGED; ARTICLE; ASTHMA; COST BENEFIT ANALYSIS; DOSE RESPONSE; DRUG CHOICE; DRUG COST; DRUG MEGADOSE; DRUG USE; ELDERLY CARE; FEMALE; HEALTH CARE PLANNING; HEALTH CARE POLICY; HEALTH INSURANCE; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MEDICARE; PRESCRIPTION; STATISTICAL MODEL; CLINICAL TRIAL; COST OF ILLNESS; ECONOMICS; INHALATIONAL DRUG ADMINISTRATION; UNITED STATES; UTILIZATION REVIEW;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; AGED; ANTI-ASTHMATIC AGENTS; ASTHMA; CLINICAL TRIALS AS TOPIC; COST OF ILLNESS; COST-BENEFIT ANALYSIS; DRUGS, GENERIC; FEMALE; HUMANS; MALE; MEDICARE PART D; UNITED STATES;

EID: 48349091445     PISSN: None     EISSN: 14726963     Source Type: Journal    
DOI: 10.1186/1472-6963-8-151     Document Type: Article

References (31)

1. Report to Congress: Medicare Payment Policy. Medicare Payment Advisory Commission (MedPAC), Washington D.C. 2007
2. Global Strategy for Asthma Management and Prevention. Global Initiative for Asthma (GINA), NIH Publication No 02-3659 2004
3. Asthma data on demand. National Center for Health Statistics, http://www.cdc.gov/nchs/health_data_for_all_ages.htm
4. Modifiable barriers to adherence to inhaled steroids among adults with asthma: it's not just black and white. AJ Apter RC Boston M George AL Norfleet T Tenhave JC Coyne K Birck ST Reisine AJ Cucchiara HI Feldman, J Allergy Clin Immunol 2003 111 6 1219 1226 10.1067/mai.2003.1479 12789220
5. Efficacy and safety of inhaled corticosteroids. New developments. PJ Barnes S Pedersen WW Busse, Am J Respir Crit Care Med 1998 157 3 Pt 2 S1 53 9520807
6. Relationship between adherence to inhaled corticosteroids and poor outcomes among adults with asthma. LK Williams M Pladevall H Xi EL Peterson C Joseph JE Lafata DR Ownby CC Johnson, Journal of Allergy and Clinical Immunology 2004 114 6 1288 1293 10.1016/j.jaci.2004.09.028
7. A cohort study showed that health insurance databases were accurate to distinguish chronic obstructive pulmonary disease from asthma and classify disease severity. J McKnight A Scott D Menzies J Bourbeau L Blais C Lemiere, J Clin Epidemiol 2005 58 2 206 208 10.1016/j.jclinepi.2004.08.006 15680756
8. Use of Census-Based Aggregate Variables to Proxy for Socioeconomic Group: Evidence from National Samples. N Krieger D Gordon, Am J Epidemiol 1999 150 892 896 10522661
9. Comparing individual- and area-based socioeconomic measures for the surveillance of health disparities: a multilevel analysis of Massachusetts births, 1989-1991. SV Subramanian JT Chen DH Rehkopf PD Waterman N Krieger, Am J Epi 2006 164 9 823 834 10.1093/aje/kwj313
10. Risk adjustment of Medicare capitation payments using the CMS-HCC model. GC Pope J Kautter RP Ellis AS Ash JZ Ayanian LI Iezzoni MJ Ingber JM Levy J Robst, Health Care Financing Review 2004 25 4 119 141 15493448
11. The Central Role of the Propensity Score in Observational Studies for Causal Effects. PR Rosenbaum DB Rubin, Biometrika 1983 70 1 41 55 10.1093/biomet/70.1.41
12. Estimating Causal Effects from Large Data Sets Using Propensity Scores. DB Rubin, Ann Intern Med 1997 127 5_Part_2 757 763 9382394
13. Misunderstanding of asthma controller medications: association with nonadherence. HJ Farber AM Capra JA Finkelstein P Lozano CP Quesenberry NG Jensvold FW Chi TA Lieu, J Asthma 2003 40 1 17 25 10.1081/JAS-120017203 12699208
14. Low-dose inhaled corticosteroids and the prevention of death from asthma. S Suissa P Ernst S Benayoun M Baltzan B Cai, N Engl J Med 2000 343 5 332 336 10.1056/NEJM200008033430504 10922423
15. Fluticasone is associated with lower asthma-related costs than leukotriene modifiers in a real-world analysis. EP Armstrong DC Malone, Pharmacotherapy 2002 22 9 1117 1123 10.1592/phco.22.13.1117.33515 12222547
16. Asthma: resource use and costs for inhaled corticosteroid vs leukotriene modifier treatment - a meta-analysis. MT Halpern ZM Khan RH Stanford KM Spayde M Golubiewski, J Fam Pract 2003 52 5 382 389 12737772
17. Inhaled fluticasone propionate. A pharmacoeconomic review of its use in the management of asthma. HM Lamb CR Culy D Faulds, Pharmacoeconomics 2000 18 5 487 510 10.2165/00019053-200018050-00008 11151402
18. Cost-effectiveness analysis of early intervention with budesonide in mild persistent asthma. SD Sullivan M Buxton LF Andersson CJ Lamm B Liljas YZ Chen RA Pauwels KB Weiss, J Allergy Clin Immunol 2003 112 6 1229 1236 10.1016/j.jaci.2003.09.025 14657888
19. Cost effectiveness of fluticasone propionate and flunisolide in the treatment of corticosteroid-naive patients with moderate asthma. T Volmer A Kielhorn HH Weber KJ Wiessmann, Pharmacoeconomics 1999 16 5 Pt 2 525 531 10.2165/00019053-199916050-00008 10662477
20. Inhaled fluticasone versus inhaled beclomethasone or inhaled budesonide for chronic asthma in adults and children. N Adams JM Bestall TJ Lasserson PW Jones, Cochrane Database Syst Rev 2005 CD002310 15846637
21. Clinical experience with fluticasone propionate in asthma: a meta-analysis of efficacy and systemic activity compared with budesonide and beclomethasone dipropionate at half the microgram dose or less. NC Barnes C Hallett TA Harris, Respir Med 1998 92 1 95 104 10.1016/S0954-6111(98)90039-7 9519232
22. A comparison of the effects of bid and qid dosing on compliance with inhaled flunisolide. M Mann O Eliasson K Patel RL ZuWallack, Chest 1992 101 2 496 499 10.1378/chest.101.2.496 1735279
23. The implications of choice: prescribing generic or preferred pharmaceuticals improves medication adherence for chronic conditions. WH Shrank T Hoang SL Ettner PA Glassman K Nair D DeLapp J Dirstine J Avorn SM Asch, Arch Intern Med 2006 166 3 332 337 10.1001/archinte.166.3.332 16476874
24. Adherence and persistence with fluticasone propionate/salmeterol combination therapy. BG Bender A Pedan LT Varasteh, J Allergy Clin Immunol 2006 118 4 899 904 10.1016/j.jaci.2006.07.002 17030244
25. Inhaled Corticosteroids for Asthma Therapy: Patient Compliance, Devices, and Inhalation Technique. MG Cochrane MV Bala KE Downs J Mauskopf RH Ben-Joseph, Chest 2000 117 2 542 550 10.1378/chest.117.2.542 10669701
26. Compliance, Adherence, and Concordance: Implications for Asthma Treatment. R Horne, Chest 2006 130 1_suppl 65S 72 10.1378/chest.130.1_suppl.65S 16840369
27. Self-reported adherence in patients with asthma. BD De Smet SR Erickson DM Kirking, Ann Pharmacother 2006 40 3 414 420 10.1345/aph.1G475 16507619
28. Effect of salmeterol on patients' adherence to their prescribed refills for inhaled corticosteroids. JS Kelloway R Wyatt J DeMarco S Adlis, Ann Allergy Asthma Immunol 2000 84 3 324 328 10752917
29. Impact of two sequential drug cost-sharing policies on the use of inhaled medications in older patients with chronic obstructive pulmonary disease or asthma. CR Dormuth RJ Glynn P Neumann M Maclure AM Brookhart S Schneeweiss, Clin Ther 2006 28 6 964 78; discussion 962-3 10.1016/j.clinthera.2006.06.007 16860179
30. Income-based drug benefit policy: impact on receipt of inhaled corticosteroid prescriptions by Manitoba children with asthma. AL Kozyrskyj CA Mustard MS Cheang FER Simons, Canadian Medical Association Journal 2001 165 7 897 902 11599328
31. Care-Seeking Behavior in Response to Emergency Department Copayments. M Reed V Fung R Brand B Fireman JP Newhouse JV Selby J Hsu, Med Care 2005 43 8 810 816 10.1097/01.mlr.0000170416.68260.78 16034295